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Abstract
Background: Neoadjuvant chemotherapy (NAC) using platinum and irinotecan (CPT-11) followed by radical excision
has been shown to be a valid treatment for locally advanced squamous cervical cancer (SCC) patients. However, in
NAC-resistant or NAC-toxic cases, surgical treatment or radiotherapy might be delayed and the prognosis may be
adversely affected. Therefore, it is important to establish a method to predict the efficacy of NAC.
Methods: Gene expression microarrays of SCC tissue samples (n = 12) and UGT1A1 genotyping of blood samples
(n = 23) were investigated in terms of their association with NAC sensitivity. Gene expression and drug sensitivity
of SCC cell lines were analyzed for validation.
Results: Microarray analysis revealed that the glutathione metabolic pathway (GMP) was significantly up-regulated in
NAC-resistant patients (p < 0.01), and there was a positive correlation between 50 % growth inhibitory concentrations
of CPT-11 and predictive scores of GMP activation in SCC cells (r = 0.32, p < 0.05). The intracellular glutathione (GSH)
concentration showed a highly positive correlation with GMP scores among 4 SCC cell lines (r = 0.72). UGT1A1
genotyping revealed that patients with UGT1A1 polymorphisms exhibited significantly higher response rates to
NAC than those with the wild-type (79.5 vs. 49.5 %, respectively, p < 0.05).
Conclusions: These results indicate that GMP scores of cancerous tissue combined with UGT1A1 genotyping of blood
samples may serve as highly potent markers for predicting the efficacy of NAC for individual SCC patients.
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Background
Despite the prevalence of screening and advancement of
therapy, the mortality rate among women of reproductive
age due to cervical cancer has increased over the last two
decades in Japan [1]. As locally advanced cervical cancer
(LACC) of FIGO stage Ib2 or IIb is frequently accompanied
by lymph node metastasis, patients bearing LACC, treated
only with excision or radiation, exhibit a high incidence
of recurrence, resulting in a poor survival outcome [2].
Thus, radical hysterectomy (RH) coupled with platinum-
based chemotherapy or radiation and concurrent chemo-
radiation therapy are now employed as intensive treatments
for LACC [3, 4]. Neoadjuvant chemotherapy (NAC) prior
to RH is usually conducted to reduce the tumor volume
and improve the safety and integrity of surgery, but the
prognosis of NAC-refractory patients worsens with the
delay of the main treatment [4]. Therefore, to optimize
the efficacy of NAC-RH, a method is needed to exclude
chemo-refractory cases before starting initial therapy.
Recently, genomic characterization by analyzing gene
expression microarrays or genotyping onco-related/sup-
pressive genes has been developed to evaluate characteristic
profiles of chemo-refractory tumors and host patients
[5, 6]. Single-sample Gene Set Enrichment Analysis
(ssGSEA) is a bioinformatics method to characterize the
biological features of individual samples as signature
scores based on gene expression microarrays [7]. It was re-
ported that the TP53 pathway ssGSEA score can be used
to predict the response of lung cancer to radiation [8], but
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there has been no report suggesting that ssGSEA is useful
to predict the chemo-susceptibility of LACC. On the other
hand, it is well-known that irinotecan (CPT-11) causes se-
vere side effects more frequently in patients with UGT1A1
polymorphisms than the wild-type [9], and, thus, UGT1A1
genotyping is a prerequisite before initiating chemother-
apy using CPT-11 in a clinical setting. However, it remains
unclear whether CPT-11 treatment is more effective in
LACC patients with UGT1A1 polymorphisms. In this
study, we assessed whether the chemo-susceptibility of
LACC could be evaluated based on tumor expression
microarray analysis and host UGT1A1 genotyping, in
order to optimize the efficacy of NAC-RH.
Methods
Sampling and intervention
A total of 209 cervical cancer patients underwent pri-
mary therapy in the 5 years between 2007 and 2012.
NAC-RH was administered to patients with stage Ib2 tu-
mors larger than 4 cm or stage IIb tumors who did not
desire radiotherapy, with 38 of the 209 patients meeting
this criterion. The clinicopathological characteristics of
these 38 LACC patients treated with NAC-RH from
2007 to 2012 at Kyoto University Hospital are summarized
in Table 1. Peripheral blood samples from 23 patients were
collected before the operation and their genomic DNA was
extracted using a QIAamp blood kit (QIAGEN, Tokyo,
Japan). Cancerous tissues were obtained from patients dur-
ing the surgery, and their RNA was extracted using the
RNeasy Mini Kit (QIAGEN). The RNA integrity number
(RIN) was assessed with a bio-analyzer, and 12 samples
with an RIN above 7.0 underwent further gene expression
analysis (Additional file 4: Table S1). All materials were
obtained following the receipt of written consent and
used based on protocols approved by the Kyoto University
Institutional Review Board. All patients received 1 to 3
courses of the combined therapy of CPT-11 and Nedaplatin
(NDP) every 3 weeks before undergoing the surgery, as pre-
viously described: CPT-11, 60 mg/m2 on days 1 and 8;
NDP, 60 mg/m2 on day 1 [10]. After the surgery, a total of
31 patients received 3 to 4 courses of CPT-11/NDP, 6 pa-
tients underwent other treatments because of CPT/NDP
resistance, and 1 patient declined postsurgical treatment.
Magnetic resonance imaging (MRI) was conducted before
initiating chemotherapy and after the completion of each
course until surgery. The tumor shrinkage rate was calcu-
lated based on the largest diameter of the target lesion on
MRI according to the response evaluation criteria in solid
tumors (RECIST) [11]. Patients underwent modified
Okabayashi’s RH [12] at the point of achieving favorable
or improbable responses after 1 (n = 4), 2 (n = 33), or 3
(n = 1) courses of chemotherapy. Adverse events during
NAC were evaluated according to the Common Ter-
minology Criteria for Adverse Events [13].
Cell lines and culture
Human cervical cancer cell lines: Ca-ski, SKGIIIa, Hela,
and ME-180, were obtained from Riken BioResource Cen-
ter (Tsukuba, Japan) and maintained in RPMI1640 (Nacalai
Tesque, Kyoto, Japan) and DMEM (Gibco, Grand Island,
NY, USA) supplemented with 10 % heat-inactivated fetal
bovine serum (v/v; Biowest, France) and penicillin–strepto-
mycin (100 IU/mL penicillin, 100 μg/mL streptomycin;
Nacalai Tesque). All of them are representative cervical
cancer cell lines, and their gene expression microarray data
could be obtained with IC50 values for CPT-11 from the
COSMIC dataset.
Microarray analysis
Transcriptional gene expression microarrays were gener-
ated from 12 cervical cancer samples using U133 Plus
2.0 gene chips (Affymetrix, Santa Clara, CA, USA), and
Robust Multi-Array Average (RMA) normalization was
performed using R (version 2.15.1). Microarray data




Median age (range) 49 (25–69)








>4 cm 30 78.9
≦4 cm 8 21.1






>50 % 25 65.8
≦50 % 13 34.2
Lymph node metastasis
negative 23 60.5
positive pelvic 15 39.5
positive aortic 4 10.5
Recurrence 10 26.3
CR Complete response, PR Partial response, SD Stable disease,
PD Progressive disease
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can be obtained at the Gene Expression Omnibus website
(GSE70035, http://www.ncbi.nlm.nih.gov/geo/). Probes
showing expression values >5.0 in at least one sample
and standard deviation >0.2 across all samples were fil-
tered to perform gene expression analysis with differen-
tially expressed genes, and the SAMROC method [14]
was used for statistical analysis, as previously described
[15]. Gene Set Enrichment Analysis (GSEA) was per-
formed using the Molecular Signatures Database (http://
www.broad. mit.edu/gsea/msigdb/index.jsp). A variant of
GSEA, single-sample GSEA (ssGSEA), was performed
using R to predict gene signature activity in squamous cell
carcinoma (SCC) cells based on the Catalogue Of Somatic
Mutation In Cancer (COSMIC, http://cancer.sanger.ac.uk/
cosmic) and HCT116 cells, colon cancer cell lines, web-
published at Array Express: E-MEXP-1171, as well as our
own samples.
UGT1A1 genotyping and glutathione assay
The Invader UGT1A1 Molecular Assay Kit (Third Wave
Technologies, Madison, WT, USA) was used to detect
UGT1A1*6 and UGT1A1*28 polymorphisms of genomic
DNA derived from blood samples. Regarding cell line
samples, the polymerase chain reaction (PCR) was carried
out to amplify the characteristic regions using designed
primers (Greiner Bio-One, Tokyo, Japan), and UGT1A1
polymorphisms were determined by direct sequencing, as
previously described [16].
Primers: UGT1A1*28 forward: 5’-TATA GTCACGT
GACACAGTC’-3 and reverse: 5’-CCACTGGGATCAA
CAGTATCT’-3, UGT1A1*6 forward: 5’-AAGTAGGAGAG
GGCGAACC’-3 and reverse: 3’-GTGGGCAGAACAGG
TACT’-3.
Total GSH concentrations in cancer cells were assayed
using the total GSH Quantification Kit (Dojindo Labora-
tories, Kumamoto, Japan) according to the manufac-
turer’s protocol.
Statistical analyses
Group comparisons were made using the Mann–Whitney
U test or Fisher’s exact test. Prognostic analyses were
performed using the Log-rank and Cox proportional haz-
ard tests. All statistical analyses were conducted using R
software. Two-side probability values below 0.05 were
considered significant.
Results
Characteristics of patients treated with NAC-RH
Clinical characteristics of the 38 LACC patients treated with
NAC-RH are listed in Table 1 (median age: 49 years old,
stage Ib2: n = 12, IIb: n = 26). Among these patients, 29
(76.3 %) exhibited a complete or partial response to NAC,
and the tumor shrinkage rate exceeded 50 % in 25 patients.
However, post-NAC pathological findings revealed node
metastasis in 19 patients, resulting in recurrence in 10 pa-
tients. In DFS analysis (Table 2), the age, tumor size, and
serum SCC values before treatment were not significant
prognostic factors. Known major risk factors of recurrence,
stage and node metastasis, were not determinants in this
study, but lymphovascular invasion (LVSI) and a tumor
shrinkage rate below 50 % exhibited significant differences
regarding DFS (p < 0.05, Table 2). The Cox proportional haz-
ard test revealed that a tumor shrinkage rate below 50 %
was an independent risk factor (RR: 12.14, p < 0.05, Table 2
and Additional file 1: Figure S1), and patients with a rate <
50 % were defined as non-responders for further analysis.
Analysis of expression profiles of clinical samples
Gene expression microarrays of 12 post-NAC tumors
were analyzed to determine the representative signature
of chemo-susceptibility in LACC, in order to compare
NAC responders (shrinkage rate≧50 %, n = 6) with
non-responders (rate <50 %, n = 6). SAMROC analysis
detected 35 genes that were significantly up-regulated
in non-responders (p < 0.001, Fig. 1), including drug-
Table 2 Univariate and multivariate analyses of factors predicting disease-free survival (n = 38)
Univariate Multivariate
RR 95 % CI P-value RR 95 % CI P-value
Age 1.149 0.3154 – 4.190 0.8328 1.162 0.1601 – 4.622 0.8607
FIGO stage 1.877 0.4963 – 7.102 0.3535 2.524 0.2284 – 27.89 0.4501
Lymph node metastasis 1.937 0.5174 – 7.248 0.3263 1.197 0.4152 – 8.85 0.4044
Parametrium invasion 3.155 0.9579 – 11.76 0.0681 1.716 0.0402 – 8.416 0.691
Margin positive 3.884 0.3645 – 685.0 0.1581 1.604 0.03867 – 10.06 0.7392
Primary tumor > 4 cm 0.3786 0.05758 – 1.266 0.1609 0.3811 0.2314 – 29.76 0.4362
Serum SCC antigen > 5.0 ng/mL 0.6878 0.1982 – 2.365 0.5545 0.2663 0.04308 – 1.646 0.1545
LVSI 8.698 1.508 – 18.00 0.011* 9.764 0.7944 – 120.0 0.07506
Shrinkage rate ≦ 50 % 6.098 2.328 – 37.18 0.0021* 12.14 1.023 – 144.1 0.04794*
RR Relative risk, CI Confidence interval, Univariate analysis, Log rank test; Multivariate analysis, Cox proportional hazard model; *significant p-value
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metabolism-related molecules such as ALDH3A1 (aldehyde
dehydrogenase 3 family, member A1) and GPX2 (gluta-
thione peroxidase 2). GSEA analysis revealed that me-
tabolism-related and DNA repair system-related pathways
were significantly up-regulated in non-responders
(Table 3). The constitutive genes of the glutathione meta-
bolic pathway (GMP) and mismatch repair pathway are
shown in Additional file 4: Table S2. In ssGSEA analysis,
the GMP score was significantly higher in non-responders
(p < 0.01), while there was no significant difference in
the mismatch repair pathway score (p = 0.1846, Fig. 2a).
The prominent expression of GMP genes, GPX2, GSS,
and GCLM, was confirmed in NAC-responders by
qPCR (Fig. 2b).
GMP score shows a positive correlation with resistance to
CPT-11
Using published COSMIC gene expression profiles of 57
SCC cell lines with half maximal inhibitory concentrations
(IC50 values) for various anticancer drugs, ssGSEA
analysis was performed. GMP scores exhibited a posi-
tive correlation with IC50 values for CPT-11 (r = 0.32,
p < 0.05, Additional file 2: Figure S2A), but not with
cisplatin. ssGSEA also showed that GMP scores of
HCT-116 cells were significantly higher in CPT-11-
resistant derivatives (p < 0.05, Additional file 2: Figure
S2B). These results indicated that the GMP score
could be a potent marker of resistance to CPT-11.
To confirm the validity of the GMP score, the total
intracellular glutathione concentration (GSH) resulting
from glutathione metabolism was assessed in the 4
cultured cervical cancer cell lines. There was a posi-
tive correlation between GSH and GMP (r = 0.72),
and, under treatment with CPT-11, apoptosis was in-
duced in Ca-ski and ME-180 cells with low GMP
and/or GSH scores in a dose-dependent manner
(Fig. 3a). Furthermore, GPX2 and GCLM were more
highly expressed in Hela and SKGIIIa cells, along
Fig. 1 Expression pattern of discriminating genes of post-NAC tumors between responders (shrinkage rate≧50 %) and non-responders (shrinkage
rate < 50 %) among 12 LACC patients. The listed genes were extracted by comparative analysis using the SAMROC method with a p-value <0.001.
Vertical columns represent individual samples, and the table at the bottom provides data on the shrinkage rate, LVSI, and UGT1A1 polymorphism.
Concerning UGT1A1 polymorphism, 1, 6, and NA indicate “UGT1A1 *1/*1 (UGT1A1-wild),” “heterozygotic polymorphism of UGT1A1 *1/*6,” and “not
available” respectively
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with a high GSH concentration (Additional file 2:
Figure S2C).
SKGIIIa exhibited a high GMP score, although it
was designated as CPT-11-sensitive (Additional file 2:
Figure S2A). Interestingly, UGT1A1 polymorphism
analysis revealed the presence of UGT1A1*28 heterozygo-
tic polymorphism in SKGIIIa cells (Fig. 3b), indicating the
contribution of host UGT1A1 polymorphisms to the sus-
ceptibility of tumors to CPT-11.
Clinical impact of UGT1A1 polymorphism
UGT1A1 genotyping of patients’ blood samples led to the
detection of heterozygotic polymorphisms (*1/*6, *1/*28)
in 11 patients (48 %, UGT1A1-poly), while almost half of
the patients were UGT1A1 *1/*1 (UGT1A1-wild), and
there were no patients with homozygotic (*6/*6, *28/*28)
or compound heterozygotic (*6/*28) polymorphisms in
this study. The tumor size was significantly reduced by
NAC in UGT1A1-poly patients (77.5 %) compared with
UGT1A1-wild patients (49.5 %, p < 0.05), although there
were no differences in severe adverse events between them
(Table 4).
Discussion
The superiority of concurrent chemoradiation therapy
(CCRT) over surgical excision for LACC due to its more
favorable local control and reduced adverse event rates
was described in a recent report [17], and CCRT is now
designated as a standard therapy for LACC. However,
CCRT has several difficulties in terms of preserving the
ovarian function, reducing late radiation-based adverse
effects, and managing pelvic lesions which remain or
recur after CCRT [18]. Thus, a therapeutically intensive
alternative has been investigated, and NAC-RH has been
designated as a reasonable alternative for LACC in terms
of not only avoiding primary radiation therapy, but also
the therapeutic intensity [19]. In this study, the response
rate to NAC using CPT-11 and NDP was 76.3 %, consist-
ent with a previous report [10] and not inferior to the
combination of cisplatin and CPT-11 [20] or paclitaxel
[21], but nearly one quarter of the cases were non-re-
sponders, and those with tumor shrinkage rates following
NAC below 50 % showed shorter PFS. This was in agree-
ment with a previous report that non-responders had poor
prognostic outcomes [22]. Thus, the shrinkage rate was an
independent prognostic factor, and it should be predicted
prior to NAC to reduce the risk of the main treatment be-
ing delayed without NAC benefits.
Pharmacogenomic analysis using gene expression mi-
croarrays with chemo-sensitivity profiles has successfully
identified several “signatures” which are characteristic
gene profiles in cancers resistant to specific anti-cancer
drugs [5], and been employed to discover novel drugs
effective against chemo-resistant cancers [23]. In this
study, GSEA showed that a mismatch repair pathway, a
Table 3 Genomic comparison between NAC-responders and non-responders. Enriched KEGG pathways in non-responders with
shrinkage rates ≦ 50 %
KEGG pathway Number of genes NES p-value q-value
Metabolism-related
METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 34 2.021684 <0.01 <0.001
DRUG_METABOLISM_CYTOCHROME_P450 36 1.987058 <0.01 0.002063
PROPANOATE_METABOLISM 29 1.925244 <0.01 0.001375
VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION 41 1.920898 <0.01 0.001179
BUTANOATE_METABOLISM 26 1.873636 <0.01 0.003011
GLUTATHIONE_METABOLISM 42 1.652794 <0.01 0.031592
DNA repair system-related
MISMATCH_REPAIR 21 1.935372 <0.01 0.00165
HOMOLOGOUS_RECOMBINATION 23 1.754282 <0.01 0.009237
BASE_EXCISION_REPAIR 33 1.62332 <0.01 0.041855
NUCLEOTIDE_EXCISION_REPAIR 42 1.588174 <0.01 0.042931
Others
DNA_REPLICATION 33 2.245259 <0.01 <0.001
CELL_CYCLE 107 2.148499 <0.01 <0.001
ALDOSTERONE_REGULATED_SODIUM_REABSORPTION 25 1.668492 0.019608 0.027948
GLYCOSYLPHOSPHATIDYLINOSITOL_GPI_ANCHOR 23 1.597785 0.017544 0.042713
KEGG Kyoto Encyclopedia of Genes and Genomes Database, NES Normalized Enrichment Score
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well-known signal of platinum-resistance, was enriched
in non-responders. ssGSEA, which quantitatively scores
the activity of each “signature” pathway in every sample
based on gene expression microarray [7], revealed that the
GMP score significantly increased in non-responders, and
that there was a positive correlation between GMP scores
and IC50 values of CPT-11 among 57 SCC cell lines.
These results suggest that GMP scores may represent the
susceptibility of LACC to CPT-11.
CPT-11 shows a strong anti-tumor activity not only
via the inhibition of DNA synthesis but also the inactiva-
tion of cystine transporters, leading to the accumulation
of reactive oxygen species (ROS) in cancer cells [24]. As
the presence of ROS is an apoptosis-inducing stress, this
mechanism associating with glutathione synthesis may
support the idea that GMP activity represents CPT-11
susceptibility. There is, however, a limitation of this
study in that GMP was identified through the analysis
of post-NAC tumors, and to apply this pathway as a
predictive biomarker of NAC susceptibility, further valid-
ation based on pre-NAC tumors is necessary. Nonetheless,
unsupervised hierarchical cluster analysis of a web-
published SCC gene expression microarray, GSE 6213,
which contains paired samples of identical patients be-
fore/after chemotherapy, revealed the following: The
gene expression pattern was not markedly affected by
chemotherapy, since cluster dendrograms did not divide
samples of each individual patient before/after chemother-
apy (Additional file 3: Figure S3). As the GMP score
showed a strong positive correlation with the total glutathi-
one concentration in SCC cells and SCC cells with low
GMP scores showed high sensitivity to CPT-11, the GMP
score might be expected to act as an NAC-susceptibility
biomarker representing intracellular glutathione synthesis.
Fig. 2 a Comparison of ssGSEA scores of glutathione metabolism and mismatch repair pathways between NAC-responders (n= 6) and non-responders
(n = 6). The Mann–Whitney U test was used for statistical analysis of the two groups. b Relative expressions of GMP genes, GPX2, GSS, and
GCLM, were compared between NAC-responders and non-responders based on quantitative PCR
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In contrast, patients with heterozygotic polymorphism
of UGT1A1 *1/*6 or *1/*28 (UGT1A1-poly patients)
showed a shrinkage rate > 50 % without a high incidence
of G3/4 toxicities. The finding that SKGIIIa cells with a
high GMP score showed UGT1A1 polymorphisms and a
high susceptibility to CPT-11 suggests that host
UGT1A1 polymorphism may constitute a complemen-
tary marker of CPT-11 susceptibility in an organ-
specific manner. In colorectal cancers, FOLFIRI con-
taining CPT-11 was more effective in patients with
UGT1A1*28/*28 polymorphism than UGT1A1-wild
patients accompanied with a decrease of SN38 glucur-
onidation in the liver [25]. Patients with homozygous
polymorphism had a much higher AUC ratio of SN-
38 than wild-type patients, whereas patients with het-
erozygous polymorphism had a slightly higher AUC
ratio than wild-type patients [25]. This may be the
reason why NAC containing CPT-11 showed a higher
efficacy without marked toxicity in patients with het-
erozygous polymorphisms. The UGT1A1 gene was
picked up as one of the chemo-refractory signature
genes in a genome-wide analysis [26], and UGT acti-
vation was observed in a colon cancer cell line which
acquired resistance to CPT-11 [27]. We considered that
the UGT1A1 genotypes of cancerous tissues matched those
of the host, although there has been no report to date on
Fig. 3 Genomic analysis of cervical cancer cell lines. a Left: Correlation analysis of GMP scores with intracellular GSH concentrations within 4
cervical cancer cell lines (n = 5). GMP scores were correlated with the total GSH concentration (r = 0.72). Right: Apoptosis was induced in each cell
line in the presence of several concentrations of CPT-11 (0, 10, or 100 μM). *: p < 0.05. n.s.: not significant. b Targeted sequencing of the UGT1A1
gene in SKGIIIa. UGT1A1*28 polymorphism is designated as two base pair insertions of TA in the TATA box within the promoter region of the
UGT1A1 gene. The A(TA)6TAA sequence in the wild-type allele become A(TA)7TAA in UGT1A1*28 polymorphism. Heterozygous UGT1A1*28
polymorphism exhibited waveform distortion downstream of the promoter region of the gene
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the correlation of UGT1A1 polymorphisms between the
tumor and host. Although further prospective studies are
needed, NAC using CPT-11 in combination with UGT1A1
genotyping might be performed more effectively and safely
than other regimens without such markers.
Conclusion
Based on comprehensive analysis, the present study sug-
gests that the GMP score and heterozygotic UGT1A1
polymorphisms may be complementary predictive markers
of CPT-11 efficacy. Other than CPT-11, a comprehensive
genomic analysis of both host and cancerous tissue might
facilitate the establishment of a novel tailored therapy
for LACC patients that exhibits high-level efficacy and
feasibility.
Additional files
Additional file 1: Figure S1. Kaplan-Meier curve for comparison of
disease free survival according to prognostic parameters, stage, lymph
node metastasis, LVSI, or shrinking rate. (PPT 124 kb)
Additional file 2: Figure S2. GMP scores in cancer cell lines. (A)
Correlation of IC50 values of CPT-11 between 57 SCC cell lines with GMP
scores. GMP scores were calculated by ssGSEA method. GMP scores
significantly correlated with IC50 values of CPT-11 (r = 0.32, p = 0.016).
Dotted black line exhibits average value of IC50. High IC50 value means to be
resistant with drug. GMP, Glutathione Metabolism Pathway; IC50, half maximal
Inhibitory concentration. (B) Comparison of GMP score between HCT-116 cell
and CPT-11 resistant derivative. CPT-11 resistant cell exhibited significantly
higher GMP score (p= 0.016). These microarray data were deposited to Array
Express as E-MEXP-1171(http://www.ebi.ac.uk/arrayexpress/). (C) Relative
expression of GMP genes, GPX2, GSS, and GCLM, in cervical cancer cell lines.
(PPT 149 kb)
Additional file 3: Figure S3. Unsupervised hierarchical cluster analysis
of a web-published SCC gene expression microarray, GSE 6213 which
contains paired samples of identical patient before/after chemotherapy.
Cluster dendrogram drawn by pvclust methods using R software exhibited
gene expression pattern was not remarkably affected during chemotherapy.
Four digits followed by X are case specific ID. Pre means samples harvested
before treatment and post means samples harvested after treatment. Values
on the edges of the clustering are p-values (%). Red values are AU
(Approximate Unbiased) p-values, and green values are BP (Bootstrap
Probability) values. Higher AU values exhibits stronger connection of
clusters. (PPT 88 kb)
Additional file 4: Table S1. Clinical information of microarray samples
of cancerous tissue. SCC: squamous cell carcinoma. NA: not available.
Table S2. Gene lists of featured pathways drawn from MSigDB (The
Molecular Signatures Database). (A) Glutathione Metabolism Pathway;
(B) Mismatch Repair Pathway. Table S3. GMP scores of 57 SCC cell lines
calculated by ssGSEA. IC 50 means 50 % inhibitory concentration of
camptothecin, downloaded from COSMIC. (DOCX 33 kb)
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